Introduction: Alzheimer\'s genetics in the 20th century
=======================================================

Alzheimer\'s disease (AD), first described by Alois Alzheimer in 1907 \[[@B1]\], is a neurodegenerative disorder progressing from memory loss to profound dementia and death within an average of eight years. Although clinical diagnosis is reliable in more than 90% of cases, the definite diagnosis is assigned post mortem based on brain atrophy and the characteristic neuropathologic findings, which involve intracellular neurofibrillary tangles containing hyperphosphorylated tau protein and extracellular amyloid plaques containing deposits of beta amyloid (Aβ). AD is recognized today as the most common cause of dementia in the elderly.

In the 1930s a number of reports described familial cases of AD with multiple affected individuals in each generation, consistent with an autosomal dominant mode of inheritance \[[@B2]-[@B4]\]. Like Alzheimer\'s first patient, the age of onset of the familial cases was most often below 65 years, which led physicians to identify AD as pre-senile dementia, distinguishing it from senile dementia. By 1980, however, it had become evident that the two types of dementia are essentially identical, named by Terry and Davies \[[@B5]\] as dementia of the Alzheimer type.

Not surprisingly, the genes involved in the familial, auto-somal dominant AD (FAD) were quickly discovered during the golden years of gene mapping in the 1990s. Despite initial confusion and controversy due to the genetic heterogeneity of AD \[[@B6],[@B7]\], extending even to the small subset of FAD, a combination of functional evidence, linkage analyses and sequence comparisons led to the identification of the three genes accounting for most FAD cases: *APP*\[[@B8]\], *PSEN1*\[[@B9]\] and *PSEN2*\[[@B10]\].

The majority (95%) of AD cases, however, are of later onset and do not follow Mendelian inheritance, despite showing significant heritability \[[@B11],[@B12]\]. Like most other psychiatric disorders, the genetics of the late-onset disease appear to be complex. AD is the first complex disorder for which a gene was identified through an association with a DNA variant, a variant in the *APOE*gene whose effect has been consistently observed since. Apolipoprotein E was known to have three common isoforms, ε2, ε3 and ε4, that are determined by two coding single nucleotide polymorphisms (SNPs). After observing high-avidity binding of Aβ to APOE, and encouraged by previous linkage reports around the *APOE*locus on chromosome 19, Strittmatter *et al*. \[[@B13]\] examined the three isoforms in cases and controls and found a significant excess of ε4 in the cases. Today, after many follow-up studies, it has been determined in populations of European descent that ε3ε4 heterozygotes have a two- to three-fold higher risk of developing AD compared to ε3ε3 homozygotes. The increase in risk for ε4ε4 homozygotes is more than twice that of the ε3ε4 heterozygotes, while ε2 heterozygotes have a reduced risk.

The significance of the identification of *APOE*as a risk factor for AD stretched beyond the obvious importance for AD research. It was a proof of principle for the \'common disease - common variant\' hypothesis that was at the time becoming increasingly popular. This result encouraged investigators to perform many candidate gene association studies for AD and other disorders; unfortunately, most did not enjoy the same degree of consistent replication.

Alzheimer\'s genetics: recent progress
======================================

Since the discovery of an association of *APOE*with AD in 1993, there have been numerous publications of genetic association studies reporting mixed results and plagued by the lack of consistent replications. Initially, most studies examined one polymorphism per gene, often without evidence that the polymorphism had any functional significance. At that time (in the mid- to late nineties) this was considered acceptable practice because little genetic variation was known and dbSNP, the database of DNA polymorphisms \[[@B14]\], did not become available until 1998. It later became clear that a more dense survey of variation in and around a gene was necessary to be confident that it has been adequately tested for association. It also became clear that it is not necessary to genotype all SNPs in a gene because, as a result of linkage disequilibrium (LD), the number of haplo-types observed in the population is lower than the possible combinations of alleles \[[@B15]\]. As the International HapMap Project \[[@B16]\] started to make data available for characterizing LD, investigators started performing more comprehensive association analyses, genotyping enough SNPs to capture and investigate all known common variations in each gene. This, however, came with the price of increased multiple comparisons, further complicating the interpretation of results. Power was reduced due to statistical corrections, while the significance of studies that identified associations for the same gene but for different SNPs was hard to interpret. In an effort to put order into these results, Bertram *et al*. \[[@B17]\] catalogued all published association studies for AD, in a public database called AlzGene \[[@B18]\]. In December 2005 the AlzGene database contained 802 different polymorphisms in 277 genes, while meta-analyses pointed to a little over a dozen of these genes as the most reliable associations \[[@B17]\]. By January 2009 the contents of the database had doubled to 557 genes and 1,852 polymorphisms. This large assembly of studies is a useful tool for AD genetics investigators around the world and it has become increasingly valuable as it incorporates more recent results from genome-wide association studies (GWAS). However, it is important to remember the inherent biases of candidate gene studies, which comprise the majority of the AlzGene database entries. Most of the reported genes were chosen because of their known functions, linkage evidence or both. In addition, it is impossible to estimate publication bias and this is itself influenced by prior linkage and functional evidence. Thus, inferences about biological pathways or further support of linkage regions based on most of these data should be avoided, with the exception perhaps of results from GWAS.

Linkage studies on late-onset AD have suffered similar limitations to those observed in association studies. Multiple genome-wide studies have been performed, often including overlapping samples, yet they have not been consistent in the genomic regions they identify and they rarely replicate each other\'s results. Only a few genomic regions including chromosomes 9, 10 and 12 have been more consistently identified by linkage \[[@B19]\]; however, the presence of risk alleles within these regions remains unproven. The success of GWAS has led investigators today to pay less attention to linkage in complex disorder, leading to a current lack of new linkage results. It must be noted that under allelic heterogeneity, linkage would be successful where association tests would fail to give a positive result. In view of FAD being caused by more than 150 different mutations in the *PSEN1*gene, it should be no surprise if the risk for late-onset AD is increased by more than ten different variants in a gene. Today it is sensible to follow the GWAS approach to find the first risk genes after *APOE*, because laboratory and analytical methods for identifying multiple rare disease-causing alleles across many genes are still in their infancy. New and emerging analytical methods and second-generation sequencing technologies will soon make it possible to explore this hypothesis in projects that will probably be guided by prior linkage and GWAS findings.

Genome-wide association studies for Alzheimer\'s disease risk loci
==================================================================

Through January 2009 there have been four reports of GWAS for AD that analyzed individual genotypes, and a report of a study that genotyped pooled samples. An additional study has used a pooling strategy to investigate potentially functional SNPs across the genome. Not surprisingly, all studies identified the *APOE*association, proving the power of the approach under the \'common disease - common variant\' hypothesis. None of these studies exceeded a sample size of 2,500 (cases and controls) and they can therefore be considered of modest size for the purpose of a GWAS. The studies have shown no overlap in terms of the identified loci other than *APOE*, and most findings have yet to be replicated by independent groups. Nevertheless, they have each reported interesting results.

The study by Grupe *et al*. \[[@B20]\] in April 2007 used a pooling strategy and multiple follow-up sample sets to examine more than 17,000 gene-based putative functional SNPs across the genome. Although only SNPs around *APOE*reached study-wide significance, many others provided weaker evidence of association, overlapping significantly with known linkage regions.

In the same month, Coon *et al*. \[[@B21]\] reported results on half a million SNPs across the genome genotyped using the Affymetrix platform on over 1,000 histopathologically verified AD cases and controls. The main conclusion of that report was that *APOE*is the only major susceptibility gene, yet in a follow-up paper, Reiman *et al*. \[[@B22]\] stratified the cases by *APOE*genotype and detected a strong association with SNPs in the *GAB2*gene, altered *GAB2*transcript levels in vulnerable neurons, and an effect of *GAB2*levels on tau phosphorylation. The association has since been tested in other samples, and although the results are conflicting \[[@B23]-[@B26]\], the occurrence of more than one independent replication \[[@B24],[@B26]\] of an association that originated from an unbiased GWAS is encouraging.

In September 2008, Abraham *et al*. \[[@B27]\] reported on a study of over 1,000 pooled cases and 1,200 pooled controls genotyped on approximately 550,000 SNPs on the Illumina platform. The authors observed only one strong signal over the *APOE*gene. Follow-up of weaker signals by individual genotyping identified the *LRAT*gene, whose product plays a prominent role in the vitamin A cascade, as another potential association with AD.

In November 2008, Bertram *et al*. \[[@B28]\] reported on a GWAS analyzing 500,000 SNPs in a sample of 410 families and using multiple other samples for replications. Using family-based tests and incorporating age of onset information, they identified a SNP on chromosome 14q31 that, like the *APOE*variants, appears to be a modifier of age of onset, while other SNPs with weaker signals were also reported. No annotated gene was found in that genomic region in the University of California Santa Cruz (UCSC) database, with the exception of a computationally predicted gene and three expressed sequence tags (ESTs). This study also found some support for the *GAB2*gene and one of the SNPs reported by the Grupe *et al*. study \[[@B20]\], while failing to support many other previous associations.

In January 2009, Beecham *et al*. \[[@B29]\] reported a GWAS on the Illumina platform analyzing approximately 550,000 SNPs in nearly 500 AD cases and 500 controls. Other than *APOE*, the study identified a SNP on chromosome 12q13 that met their criterion for genome-wide significance, a false-discovery rate of less than 0.20. This association was replicated in an independent sample, and it lies in a genomic region that has been previously reported to show significant genetic linkage to the disease \[[@B30]-[@B33]\]. Perhaps most interestingly, the authors reported that out of the 19 best distinct signals, 12 were found in regions with prior linkage evidence, consistent with the expectation of enrichment for true signals \[[@B34]\].

Carrasquillo *et al*. \[[@B35]\] have recently published a GWAS for AD on 844 cases and 1,255 controls, using an Illumina platform to assay approximately 314,000 SNPs. Although in their stage 1 analysis only APOE SNPs reached genome-wide significance, a signal on chromosome X provided strong evidence in the replication samples, giving a combined *P*-value as low as 3.9 × 10^-12^. This signal was within the *PCDH11X*gene, which encodes a protocadherin, a cell-cell adhesion molecule expressed in the brain.

It is still too early to draw definite conclusions from the results of the reported GWAS for AD. The sample sizes analyzed are considerably smaller than those of GWAS that have successfully identified genes for other complex disorders \[[@B36]\]. For example, a large GWAS of seven major diseases involving approximately 2,000 cases of each disease and approximately 3,000 controls successfully identified associations for five disorders but showed much weaker results for bipolar affective disorder and hypertension \[[@B37]\], indicating that this sample size is adequate for some but not all complex diseases. Some of the reported associations for AD will probably point to new genes as more investigators replicate them and further analyze the variants functionally; however, it appears that the GWAS on AD might still be underpowered and the effect sizes of the remaining AD-associated variants are as small as those seen in other GWAS. In other words, it becomes more and more clear that *APOE*is the exception rather than the rule, making AD an interesting case of a complex disorder that involves single genes with Mendelian transmission and extensive allelic heterogeneity, one gene with common allelic variation and a considerable effect on the risk and the age of onset, and multiple other variants with seemingly smaller effects. With a few genes already in hand, with the first GWAS opening the way for more to follow, and with new sequencing technologies emerging and promising to test the possibility of multiple rare variants, these are exciting times for AD genetics research.

Contribution of AD genetics to treatment and diagnosis
======================================================

It is now more than 15 years since the discovery of the first genes involved in AD, and while we are still on a quest for additional genes, we have learned a lot about the disease. The processing of APP through cleavage by γ-secretase, an enzymatic complex whose catalytic subunit is formed by the presenilins \[[@B38]\], is considered by many as a key in the disease process. It leads to generation of the amyloidogenic peptide Aβ (Figure [1](#F1){ref-type="fig"}) and its aggregation into fibrils and toxic oligomeric forms, the earliest effectors of synaptic compromise \[[@B39]\], followed by neurodegeneration. The direct involvement of the products of at least three out of the four known genes in this hypothesis is no coincidence and significantly strengthens the confidence that this is a promising target for treatment. These genes have greatly enhanced our knowledge of the pathway leading to the production of amyloid (Figure [1](#F1){ref-type="fig"}), which has in turn provided targets for intervention.

![**The amyloidogenic and non-amyloidogenic cleavage pathway of APP**. Mutations in *APP*, *PSEN1*or *PSEN2*cause early-onset AD. PSEN1 and 2 are components of γ-secretase. The amyloidogenic peptide Aβ is shown in orange. reliable associations from GWAS, the best targets and strategies to intervene will become clearer.](gm34-1){#F1}

Treatments targeting APP processing include those diverting cleavage toward the non-amyloidogenic α-secretase pathway (α-secretase enhancers) and those inhibiting the amyloido-genic pathway of beta and gamma secretase (β- or γ-secretase inhibitors). Pharmacological agents that enhance α-secretase activity include, among others, non-steroidal anti-inflammatory drugs (NSAIDs), statins and estrogens through activation of protein kinase C \[[@B40]\]. These agents have been tested with varying results. The effectiveness of estrogens has been suggested by many *in vitro*and *in vivo*studies; however, data from the Women\'s Health Initiative Memory Study \[[@B41]\], a large randomized controlled trial, did not show a consistent positive effect. The possibility that there is a critical period for neuroprotection \[[@B42]\] and that genetic variation or other predisposing factors might modify the effects of estrogens requires further examination \[[@B43]\]. The use of NSAIDs has seen support from epidemiological studies as likely to reduce the risk for the disease; however, the results of clinical investigations so far have not been encouraging \[[@B44],[@B45]\]. The use of statins for AD prevention has shown conflicting results. Initial cross-sectional studies showed risk reductions that were better than 50% (for a review see Rockwood *et al*\[[@B46]\]). Clinical trials and cohort studies, however, failed to show the protective effect that has been consistently observed in cross-sectional studies \[[@B46]\].

The possibility of indication bias in cross-sectional studies (that is, people with AD are less likely to receive statin treatment) cannot be ruled out, although it has been accounted for by some studies \[[@B46]\]. The debate and interest in statins remains open, as support from prospective clinical trials is clearly necessary before they can be considered a preventive measure for AD \[[@B47]\]. The recognition that *ADAM10*from the ADAM family of metalloproteases exhibits α-secretase activity \[[@B48]\] and is regulated by retinoic acid \[[@B49]\] has led to the inclusion of retinoic acid in the list of potential therapeutic agents \[[@B50]\]. Retinoic acid has shown promising results in an AD mouse model \[[@B51]\] but its potential as a therapeutic agent for AD in humans has not yet been examined.

Agents that inhibit the amyloidogenic pathway include β-and γ-secretase inhibitors. Beta-secretase inhibitors have only recently been developed \[[@B52]\], and initial tests on transgenic mice are positive, showing decreased Aβ production \[[@B53]\]. Gamma-secretase inhibitors have also shown positive results in laboratory animal models and, administered in low doses, they are safe in humans and reduce plasma Aβ \[[@B54]\]. A major limitation in the use of these inhibitors is that APP is not the only substrate of γ-secretase. Other substrates include NOTCH, ERBB4 and many other type I membrane protein stubs \[[@B54]\]; therefore, significant inhibition of the enzyme could lead to serious side-effects. This limitation might be bypassed to some extent as more selective agents are developed.

The role of *APOE*in AD appears to be more complex than that of *APP*and the presenilins. Studies of its functional involvement have implicated the homeostasis of cholesterol and phospholipids, synaptic integrity, amyloid metabolism, phosphorylation of tau, accumulation of neurofibrillary tangles and neuronal survival \[[@B55]\]. Nevertheless, *APOE*is an important player in pharmacological intervention research. Many studies have suggested that the *APOE*genotype can influence the outcome of existing treatments \[[@B56]\], making it interesting from a pharmacogenetics perspective, while others have suggested that targeting the regulation of *APOE*expression is a potential treatment approach \[[@B55],[@B57]\]. Interestingly, drugs that modify the expression of *APOE*include statins which, as discussed above, have already shown promise.

Many of the genes that have been implicated in AD - albeit not consistently - by association studies are involved in multiple aspects of the disease \[[@B58]\], including the generation of neurofibrillary tangles, amyloid aggregation, amyloid clearance, oxidative stress and hypoxia, inflammation and apoptotic cell death. Most of these processes are already targeted by therapeutic agents either directly or through effects of drugs chosen to target other disease mechanisms. When the validity and exact nature of the genetic associations is elucidated in the near future, together with new reliable associations from GWAS, the best targets and strategies to intervene will become clearer.

At the level of molecular genetic diagnosis and risk assessment, there is a sharp divide between early- and late-onset disease. In FAD, mutations in one of three genes (*APP*, *PSEN1*and *PSEN2*) can be found in more than 80% of patients \[[@B59]\]. Although there is currently no effective cure or prevention strategy, knowledge of the risk, and prenatal diagnosis, might be desired and is possible. For late-onset AD, however, our current knowledge does not allow useful genetic testing. The increase in risk by *APOE*ε4 is of questionable use as most carriers will not become affected and half of the patients do not carry this allele. This is even more questionable for less established genetic associations. As we begin to discover more and more genes and genetic variants involved in AD and learn the details of their functions and interactions with each other and the environment, it is most likely that one day in the not so distant future accurate risk and age of onset prediction will become a reality. Such capability, combined with strategies for prevention and effective treatments, perhaps tailored to each patient through pharmacogenetics, could lead to solving this major public health problem.

Conclusion
==========

Initial successes in relation to the genetics of AD were followed by frustration as investigators addressed the more common and genetically complex late-onset disease. The four AD genes identified in the 1990s provided important knowledge on the disease pathogenesis at the molecular level. While no new gene has been positively identified since then, there is a wealth of new data from potentially important genetic linkage and association studies. As powerful tools for high-throughput DNA analysis are becoming available, the first GWAS are emerging, and extensive DNA sequencing studies will probably follow. Those will soon lead to further breakthroughs, improving our understanding of genetic risk, and allowing better gene-based approaches to prevention and treatment.
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